ClinicalTrials.gg
CompletedNCT05346601Updated Feb 9, 2023

Trial of Chiauranib Capsule on Pharmacokinetics to Assess the Effect of High Fat Diet in Healthy Volunteers

A Phase 1 interventional study of Chiauranib in Healthy Volunteers, sponsored by Chipscreen Biosciences, Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-02-09.

Sponsored by Chipscreen Biosciences, Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

The purpose of this study is to further study the pharmacokinetic characteristics of Chiauranib Capsule in Healthy Volunteers with High Fat Diet.

Read the detailed description

This study is a Randomized, Open-label, Single-dose, Single-center, two-sequence, two- stage Phase I Trial. 16 Healthy Volunteers will be enrolled and Randomized into two arms. 8 Healthy Volunteers were in each arm. Arm A:Patients receive 50mg Chiauranib po only once In the fasting state and after 14 days receive 50mg Chiauranib po Only once with High Fat Diet. Arm B: Patients receive 50mg Chiauranib po only once with High Fat Diet and after 14 days receive 50mg Chiauranib po Only once In the fasting state. During the trial, Blood samples were collected.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Chipscreen Biosciences, Ltd. is the lead sponsor of 42 studies on the registry; 11 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Ages: 18 Years to 45 Years
  2. 19≤≤26. Weight of male ≥50 kg and Weight of female 45 kg
  3. at screening Healthy or NCS as determined by the Investigator based on physical examination, vital signs, a series of laboratory examinations(such as blood routine examination, et.al)and 12-lead (ECG)
  4. Healthy Volunteers have no plan to fertilize throughout treatment and for at least 6 months after study is stopped
  5. Healthy Volunteers voluntarily sign
  6. Able to communicate well with the Investigator, to comply with the requirements of the study

Exclusion criteria

Exclusion Criteria:

  1. Has known allegies to Chiauranib ,any of the or Have a history of relevant atopy or drug
  2. Being hypertension or having risk of hypertension, or SBP≥140 mmHg, DBP ≥90 mmHg; or Being hypotension or having risk of hypotension, or SBP \< 90 mmHg, DBP \< 60 mmHg
  3. Inability to take oral medication or having Gastrointestinal, liver and kidney diseases that affect drug absorption or metabolism within 6 months
  4. Prior to random Having uncured diarrhea or having 4 or more episodes of diarrhea within 7 days prior to scheduled drug administration
  5. Having any significant history of hemorrhagic disease or any history of coagulopathy
  6. A history of frequent and severe infection(≥3 episodes)within the past 1 year, or a history of severe infection within 3 months prior to drug administration;
  7. Ccr \< 80 mL/min
  8. Difficulty of venous blood collection
  9. > 450 ms
  10. Drug abuse within 5 years or used drug within 3 months prior to the study, or Urine drug screening is positive during screening
  11. Heavy smokers(average daily smoking of more than 5 cigarettes/ day during past 3 months prior to screenig); heavy drinkers(average weekly drinking of more than 14 units of alcohol during past 6 months prior to screening, 1 unit =360 mL beer or 45 mL 40% spirits or 150 mL wine); Having Alcoholic products within 2 days prior to drug administration, or Alcohol breath test result ≥20 mg/dl
  12. Ingestion of prescription drugs, OTC drug, Vitamin, dietary supplements or herbal products within 14 days prior to screening
  13. Subjects who have taken any drugs known to induce or inhibit hepatic drug metabolism(, CYP1A2 and CYP2D6)within 30 days prior to drug administration of the study medication, or Subjects who have taken any foods and drinks known to induce or inhibit hepatic drug metabolism within 7 days prior to drug administration
  14. Intake of Tea, Coffee or other Caffeinated beverage(more than 8 cups, 1 cup=250 mL)within 14 days prior to drug administration, Intake of any food or beverage containing or metabolized to produce caffeine or xanthine within 48 hours prior to drug administration
  15. Subjects with evidence of cardiovascular, gastrointestinal/hepatic, renal, psychiatric, respiratory, urogenital, hematologic/immunologic, HEENT (head, ears, eyes, nose, throat), dermatological/connective tissue, musculoskeletal, metabolic/nutritional, drug hypersensitivity, allergy, endocrine, major surgery or other relevant diseases as revealed by medical history, physical examination, and laboratory assessments which may interfere with the absorption, distribution, metabolism or elimination of drugs or constitute a risk factor when taking study medication
  16. A positive result in surface antigen (HBsAg), anti- virus (HCV) antibodies, a syphilis test, or an (HIV) test
  17. The abnormal result of C-reactive protein has clinical significance or Subjects testing positive for COVID-19
  18. Vaccinated within 1 month prior to screening or plan to Vaccinate during the study
  19. Females with a positive pregnancy test or Women of , pregnant and lactating women
  20. Volunteer in any other study within 3 months prior to drug administration, or Volunteer in 3 times or more studies
  21. Blood donation or lost more than 400mL blood within 3 months prior to the study, or Received blood transfusions within 1 month
  22. Patients received major surgical operations within 6 months prior to screening, or plan to received surgical operation during the study
  23. Extremes in food consumption practices
  24. Other situations that the researchers considered unsuitable to enroll the subject
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Other
    Chiauranib(In the fasting state)

    Experimental: Chiauranib Patients receive 50mg Chiauranib po only once In the fasting state and after 14 days receive 50mg Chiauranib po Only once with High Fat Diet

    Drug: Chiauranib

  • Other
    Chiauranib(In the high fat diet state)

    Experimental: Chiauranib Patients receive 50mg Chiauranib po only once with High Fat Diet and after 14 days receive 50mg Chiauranib po Only once In the fasting state

    Drug: Chiauranib

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics of Chiauranib (in plasma)

    Peak plasma concentration for Chiauranib(Cmax)

    Time frame: up to 20 Days

  2. Pharmacokinetics of Chiauranib (in plasma)

    Area under the concentration-time curve from zero to last quantificable concentration for Chiauranib (AUC0-t)

    Time frame: up to 20 Days

  3. Pharmacokinetics of Chiauranib (in plasma)

    Area under the concentration-time curve from zero extrapolated to infinity for Chiauranib(AUC0-inf)

    Time frame: up to 20 Days

Secondary outcomes

  1. Pharmacokinetics of Chiauranib (in plasma)

    Time to Cmax for Chiaruanib(Tmax)

    Time frame: up to 20 Days

  2. Pharmacokinetics of Chiauranib (in plasma)

    Elimination half-life(t1/2)

    Time frame: up to 20 Days

  3. Pharmacokinetics of Chiauranib (in plasma)

    Apparent clearance(CL/F)

    Time frame: up to 20 Days

  4. Pharmacokinetics of Chiauranib (in plasma)

    Apparent volume of distribution(Vd/F)

    Time frame: up to 20 Days

  5. Pharmacokinetics of Chiauranib (in plasma)

    Elimination rate constant(λz)

    Time frame: up to 20 Days

07

Study locations

1 site
  • The First Affiliated Hospital of Suzhou University
    Suzhou, Jiangsu 21500, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2022 to primary completion in Jun 2022, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 14, 2022
First posted
Apr 26, 2022
StartActual
Jun 2, 2022
Primary completionActual
Jun 28, 2022
CompletionActual
Jun 28, 2022
Last update
Feb 9, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 9, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05346601
Collaborators
H & J CRO International, Inc.
Responsible party
Sponsor
First posted
Apr 26, 2022
Start date
Jun 2, 2022
Primary completion
Jun 28, 2022
Completion
Jun 28, 2022
Last update
Feb 9, 2023

Study contacts

LiYan Miao
principal investigator · First Affiliated Hospital of Suzhou Medical College

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Chiauranib

Start the discussion